Planet 13 Holdings Inc. cultivates and provides cannabis products for the medical and retail markets in the U.S. A key strength is its gross margin of 53.9%, indicating solid product profitability; however, concerns arise from negative EBITDA and net margins, suggesting operational inefficiencies. The current ratio of 1.80 reflects good liquidity, but a debt-to-equity ratio of 1.39 raises leverage concerns. Overall, while the company has strong margins, its financial health is hindered by ongoing losses and high debt levels.
Loading financial metrics...
Company posted a loss of $-62.3M over the last year, representing 67.3% of revenue.
Debt of $53.9M is 3.3x the company's cash position of $16.5M.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)